Moscow – Given the country’s first COVID-19 vaccine, at least four Russian health workers have contracted coronovirus, as its developers claim that human testing their formula is 92% effective. Effectiveness from the government-run lab claims that the vaccine developed on the heels of the American pharmaceutical giantData is showing that the vaccine is 90% effective in association with a German company.
Russian CommentaryEven as a safe, effective drug by the country’s regulatory body named Sputnik V in August, it was undergoing Phase 3 human trials.
Pharmaceutical companies have worked with government agencies in many countries, in unprecedented public-private initiatives, a 10-year process to approve and bring in a generally effective vaccine.
Many companies including Pfizer haveEven with ongoing trials for example, but they have not yet been permitted by the regulatory bodies of any Western countries to administer their vaccines to those not enrolled in clinical trials.
However, in Russia, authorities have given Sputnik V medicine and teachers nationwide from summer, separate and clinical trials. The head of the laboratory behind the Sputnik vaccine said this week that as many as 50,000 people – again, not clinical trial participants – have been given the vaccine.
Altai’s Siberian region officials reported on Tuesday that three of the 42 people receiving the two-dose Sputnik V vaccine had become infected with the coronavirus after taking their first shot, but said it was because the drug was not A chance to work, not because it was ineffective.
The area’s Ministry of Health stated, “The chances of immunity from sick doctors were not until they encountered the COVID-19 pathogens.” “Only this can be the reason for the infection of doctors.”
On Thursday, the Health Ministry in another Siberian region, Kuzbas, said a doctor there had received only the first of his two Sputnik V injections, which tested positive for COVID-19. According to Russia’s state news agency RIA Novosti, the ministry also blamed the infection before the drug had a chance to increase immunity in the patient.
According to the government-run Gamelea Research Institute of Epidemiology and Microbiology, which developed Sputnik V, complete immunity would not be expected until three weeks after the second dose was administered. The Ministry of Health said in a statement on Wednesday that intermediaries in Altai received their first vaccine injections between 25 and 30 September and they fell ill between seven and 10 days.
Sputnik vaccine testing has found few confirmed cases of coronavirus infection among volunteers. The Gamalaya Center has combed down those reports, suggesting that infected volunteers had received a placebo instead of the actual vaccine.
“Sputnik V vaccine efficacy was 92%,” the lab said on its official Twitter page Wednesday. It stated that efficacy ratings were based on results showing approximately 20 people who participated in the trial between vaccine and placebo recipients contracted the disease.
The numbers were released two days after Pfizer announced its test data showing more than 90% efficacy for its formula – according to reports seized by doctors, epidemiologists and politicians, of the world’s most efficient development Tide on the epidemic as the race to turn on any vaccine to date.
Many doctors and scientists in Russia and globally are skeptical of the country’s unusual move to register the vaccine for use before completing the test, but Russia’s government has rejected criticism, asserting that That early testing proved Sputnik V safe and effective. President Vladimir Putin said that one of his daughters had been given the vaccine before it was officially registered.
As of Thursday, officials said more than 20,000 people were given the first dose of the vaccine under Phase 3 human testing, and more than 16,000 people received both shots. Eventually, about 40,000 people are expected to participate in the Sputnik test.
By comparison, the Phase 3 trial for the Pfizer vaccine saw around 39,000 people when preliminary testing data was announced by the company earlier this week.
Russia has seen a record number of deaths and new COVID infections in recent times. Authorities have gradually re-enforced the sanctions to try to slow the spread of the virus, while promising not to roll back a full national lockdown. Mass vaccination is an important part of the government’s epidemic response plan.
The head of the Gamalaya Center, Alexander Gintesburg, said on Wednesday that the post-registration test on Sputnik V would be completed around May or June according to the RIA. But he also said that the interim results should be sufficient for the introduction of mass vaccination of the Russian population in the coming weeks.
Russia has already registered a second vaccine, and the government says that a third may be approved next month.
However, the production of vaccine doses estimated by Russian authorities is a slow process.
On Wednesday, Deputy Prime Minister Tatyana Golikova stated that Russia planned to produce 2 million doses of Sputnik V by the end of the year, and to release up to 6 million doses per month from April 2021.
Pfizer said this week that it expected to “produce 50 million vaccine doses globally this year alone.” AstraZeneca of Britain has already produced millions of doses of its vaccine, which it expects the data to be effective within weeks.
Pfizer said it would likely have enough Phase 3 trial data later this month for the Emergency Use Authority for its vaccine to apply to the US Food and Drug Administration.